Cancer Research and Biotechnology AG (CRaB) is a preclinical biopharma company, developing a treatment for cancer, and other degenerative diseases, based on its discovery and innovation in reverse oncogenesis. The proprietary compounds have been studied and patented by CRB, and in vitro proof of concept is documented. We found that cancer can be curable as a metabolic disease by origin. CRB is developing innovations to reverse the cellular processes leading to mitochondrial dysfunctions, and other causes of tumors and degeneration. Healthy aging is a reality.